Beta Cell Function is Disrupted in Patients with Systemic Lupus Erythematosus

• Published in: Rheumatology (Oxford, England) England), 2021-08, Vol.60 (8), p.3826-3833
• Main Authors: García-Dorta, Alicia, Quevedo-Abeledo, Juan Carlos, Rua-Figueroa, Íñigo, de Vera-González, Antonia M, González-Delgado, Alejandra, Medina-Vega, Lilian, González-Rivero, Agustín F, Francisco-Hernández, Felix, González-Gay, Miguel A, Ferraz-Amaro, Iván
• Format: Article
• Language: English
• ISSN: 1462-0324; 1462-0332
• DOI: 10.1093/rheumatology/keaa874

To investigate how markers of beta cell secretion (proinsulin-processing metabolites) are expressed in systemic lupus erythematosus (SLE) patients and their potential relation to features associated with the disease such as activity or damage. 144 SLE patients and 69 nondiabetic sex- and age-matched controls were assessed. Beta-cell secretion molecules, as measured by insulin, split and intact proinsulins, and C-peptide levels were analyzed in both groups. Multiple regression analysis was performed to compare proinsulin propeptides between groups and to explore the interrelations with SLE features. Analyses were adjusted for glucocorticoid intake and for insulin resistance classic risk factors. Fully multivariable analysis demonstrated that regardless of glucocorticoid use, SLE patients exhibited higher levels of split proinsulin. Likewise, the split proinsulin-to-insulin ratio was upregulated in patients with SLE undergoing glucocorticoid therapy (beta coef. 0.19 [95%CI 0.07-0.30], p= 0.002) or not (beta coef. 0.09 [95%CI 0.01-0.17), p= 0.025). Similar results were found for the intact proinsulin-to-insulin ratio, although differences were only statistically significant for patients taking glucocorticoids (beta coef. 0.08 [95%CI 0.03-0.12], p= 0.001). SLE damage score was associated with higher serum levels of intact (beta coef. 0.51 [95%CI 0.17-0.86] pmol/l, p= 0.004) and split proinsulins (beta coef. 1.65 [95%CI 0.24-3.06] pmol/l, p= 0.022) after multivariable analysis, including disease duration and prednisone use. Among patients with SLE, proinsulin-processing metabolites, a marker of beta-cell disruption, are upregulated compared with matched controls. This disproportionate hyperproinsulinemia can be explained by the damage produced by the disease and occurs independently of prednisone use.